Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Prexasertib |
| Synonyms | |
| Therapy Description |
Prexasertib (LY2606368) inhibits checkpoint kinase 1 (Chk1), which may result in accumulation of DNA damage and decreased tumor growth (PMID: 26141948, PMID: 28270495, PMID: 32539469, PMID: 32510664). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Prexasertib | LY2606368|IC-83|ACR-368|ACR368|ACR 368 | CHK1 Inhibitor 18 | Prexasertib (LY2606368) inhibits checkpoint kinase 1 (Chk1), which may result in accumulation of DNA damage and decreased tumor growth (PMID: 26141948, PMID: 28270495, PMID: 32539469, PMID: 32510664). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04032080 | Phase II | Prexasertib LY3023414 | Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST) | Completed | USA | 0 |
| NCT03414047 | Phase II | Prexasertib | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | Completed | USA | ITA | ISR | GBR | ESP | BEL | AUS | 1 |
| NCT02555644 | Phase I | Prexasertib Cisplatin Cetuximab | A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer | Completed | USA | FRA | 0 |
| NCT02203513 | Phase II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | Terminated | USA | 0 |
| NCT02873975 | Phase II | Prexasertib | A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | Completed | USA | 0 |
| NCT02735980 | Phase II | Prexasertib | A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | TUR | NLD | GRC | GBR | FRA | ESP | DEU | 2 |
| NCT02808650 | Phase I | Prexasertib | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
| NCT05548296 | Phase Ib/II | Prexasertib Gemcitabine + Prexasertib | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Recruiting | USA | 0 |
CKB BOOST